Co-expression of ERCC1 and Snail is a Prognostic but Not Predictive Factor of Cisplatin-based Neoadjuvant Chemotherapy for Bladder Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2012 Jul 19

PMID 22807952

Citations 7

Authors

Atsunari Kawashima

Hitoshi Takayama

Norihiko Kawamura

Noriteru Doi

Mototaka Sato

Koji Hatano

Akira Nagahara

Motohide Uemura

Yasutomo Nakai

Kensaku Nishimura

Susumu Miyoshi

Kiyoshi Kawano

Kazuo Nishimura

Norio Nonomura

Akira Tsujimura

Affiliations

Soon will be listed here.

Abstract

Neoadjuvant chemotherapy (NC) for bladder cancer has been reported to significantly improve the 5-year survival rate. The aim of the present study was to examine the roles of ERCC1 and Snail in determining the response to chemotherapy in bladder cancer treated with NC and radical cystectomy (RC). The expression of the Snail and ERCC1 proteins was determined by immunohistochemical staining of specimens obtained from 58 patients with bladder tumors treated with NC and RC. The correlation between clinical response and the expression of Snail and ERCC1 was investigated. Snail and ERCC1 were co-expressed in 24 (41.4%) of the 58 patients. A marked correlation was found between the expression of Snail and ERCC1 (P=0.001). The co-expression of Snail and ERCC1 was not able to predict pathological complete response (P=0.202). Results of the univariate analysis revealed that the co-expression of Snail and ERCC1 predicted shorter disease-free survival (DFS) and overall survival (OS) than the negative expression of Snail and/or ERCC1. Moreover, the co-expression of ERCC1 and Snail was the only predictive factor for both DFS (P=0.029) and OS (P=0.040). The expression of Snail was correlated with that of ERCC1 and the co-expression of Snail and ERCC1 was the only significant predictive factor of shorter DFS and OS in patients with bladder cancer treated with NC and RC.

Citing Articles

Prognostic value of nucleotide excision repair and translesion DNA synthesis proteins in muscle-infiltrating bladder carcinoma.

Palacka P, Holickova A, Roska J, Makovicky P, Vallova M, Biro C BMC Cancer. 2024; 24(1):1103.

PMID: 39237917 PMC: 11376035. DOI: 10.1186/s12885-024-12865-8.

Clinical Perspectives of ERCC1 in Bladder Cancer.

Koutsoukos K, Andrikopoulou A, Dedes N, Zagouri F, Bamias A, Dimopoulos M Int J Mol Sci. 2020; 21(22).

PMID: 33266377 PMC: 7700570. DOI: 10.3390/ijms21228829.

Lessons learned from SMAD4 loss in squamous cell carcinomas.

Hernandez A, Young C, Wang J, Wang X Mol Carcinog. 2019; 58(9):1648-1655.

PMID: 31140647 PMC: 6820000. DOI: 10.1002/mc.23049.

Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy: A Prisma-Compliant Meta-Analysis.

Qixing M, Gaochao D, Wenjie X, Rong Y, Feng J, Lin X Medicine (Baltimore). 2015; 94(39):e1593.

PMID: 26426637 PMC: 4616831. DOI: 10.1097/MD.0000000000001593.

Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma.

Xiao X, Wang W, Zhang H, Gao P, Fan B, Huang C Tumour Biol. 2014; 36(4):2427-35.

PMID: 25431261 DOI: 10.1007/s13277-014-2853-5.

References

Takata R, Katagiri T, Kanehira M, Shuin T, Miki T, Namiki M . Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci. 2006; 98(1):113-7. PMC: 11158918. DOI: 10.1111/j.1349-7006.2006.00366.x. View

Hsu D, Lan H, Huang C, Tai S, Chang S, Tsai T . Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res. 2010; 16(18):4561-71. DOI: 10.1158/1078-0432.CCR-10-0593. View

Winquist E, Kirchner T, Segal R, Chin J, Lukka H . Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004; 171(2 Pt 1):561-9. DOI: 10.1097/01.ju.0000090967.08622.33. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

Sayan A, Griffiths T, Pal R, Browne G, Ruddick A, Yagci T . SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci U S A. 2009; 106(35):14884-9. PMC: 2736415. DOI: 10.1073/pnas.0902042106. View

Gossage L, Madhusudan S . Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev. 2007; 33(6):565-77. DOI: 10.1016/j.ctrv.2007.07.001. View

Matsumura N, Nakamura Y, Kohjimoto Y, Inagaki T, Nanpo Y, Yasuoka H . The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. BJU Int. 2010; 108(2 Pt 2):E110-6. DOI: 10.1111/j.1464-410X.2010.09932.x. View

Kim K, Do I, Kim H, Chang M, Kim H, Jun H . Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. APMIS. 2010; 118(12):941-8. DOI: 10.1111/j.1600-0463.2010.02648.x. View

Matsui Y, Nishiyama H, Watanabe J, Teramukai S, Ono Y, Ohshima S . The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan. Int J Clin Oncol. 2005; 10(2):133-8. DOI: 10.1007/s10147-004-0474-5. View

10.

Bruyere F, Namdarian B, Corcoran N, Pedersen J, Ockrim J, Voelzke B . Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers. Urol Oncol. 2009; 28(6):591-6. DOI: 10.1016/j.urolonc.2008.11.005. View

11.

Pinho M, Costas F, Sellos J, Dienstmann R, Andrade P, Herchenhorn D . XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy. Urol Oncol. 2008; 27(4):382-90. DOI: 10.1016/j.urolonc.2008.03.016. View

12.

Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T . Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005; 11(7):2625-36. DOI: 10.1158/1078-0432.CCR-04-1988. View

13.

Park C, Bessho T, Matsunaga T, Sancar A . Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J Biol Chem. 1995; 270(39):22657-60. DOI: 10.1074/jbc.270.39.22657. View

14.

Hoffmann A, Wild P, Leicht C, Bertz S, Danenberg K, Danenberg P . MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia. 2010; 12(8):628-36. PMC: 2915407. DOI: 10.1593/neo.10402. View

15.

Arumugam T, Ramachandran V, Fournier K, Wang H, Marquis L, Abbruzzese J . Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009; 69(14):5820-8. PMC: 4378690. DOI: 10.1158/0008-5472.CAN-08-2819. View

16.

Olaussen K, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V . DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355(10):983-91. DOI: 10.1056/NEJMoa060570. View

17.

Font A, Taron M, Gago J, Costa C, Sanchez J, Carrato C . BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol. 2010; 22(1):139-144. DOI: 10.1093/annonc/mdq333. View

18.

Ko J, Su Y, Lin S, Jhan J, Ciou S, Cheng C . Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochem Pharmacol. 2009; 79(4):655-64. DOI: 10.1016/j.bcp.2009.09.024. View

19.

Kawashima A, Nakayama M, Kakuta Y, Abe T, Hatano K, Mukai M . Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin Cancer Res. 2010; 17(8):2561-9. DOI: 10.1158/1078-0432.CCR-10-1963. View

20.

Stenzl A, Cowan N, De Santis M, Jakse G, Kuczyk M, Merseburger A . The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009; 55(4):815-25. DOI: 10.1016/j.eururo.2009.01.002. View